首页 > 最新文献

Frontiers in reproductive health最新文献

英文 中文
Preterm birth and stillbirth during COVID-19 pandemic in Bihor County/Romania. 比霍尔县/罗马尼亚 COVID-19 大流行期间的早产和死胎。
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI: 10.3389/frph.2024.1286496
Radu Galis, Paula Trif, Diana Mudura, Romina Murvai, Lucia Georgeta Daina, Florin Szasz, Rodica Negrini, Adrian Hatos, Beáta Fatime Gyarmati, Mandy C Daly, Jan Mazela, Boris W Kramer

Background: International studies have reported conflicting data about the effects of COVID-19 pandemic policy measures on maternal and neonatal health. A major impact was reported on stillbirth and prematurity. The published literature suggests that the economic setting influenced the effects of imposed mitigation measures with a more severe effect in low-income countries.

Objectives: Our objective is to compare pregnancy outcomes at the only tertiary Maternity Hospital in Bihor County-Romania before and during the COVID-19 pandemic. This study aims to observe and document differences in perinatal outcomes across these periods, without inferring direct causation related to the pandemic or its associated restrictions.

Materials and methods: We used data from the registries of Public Health Services Bihor to conduct a retrospective cohort analysis of preterm births and stillbirths during the COVID-19 pandemic in Bihor County, Romania. Pregnancy outcomes were compared between the pandemic period (March 2020-February 2022) to the corresponding historical pre-COVID-19 period (March 2018-February 2020). Maternal socio-demographic variables and neonatal characteristics of these periods were also examined.

Results: The COVID-19 pandemic period was associated with an increase in the stillbirth rate (RR: 1.53, 95% CI, 1.05-2.23). Preterm birth was significantly impacted during this period and showed changes when analyzing gestational age (RR: 0.88, 95% CI, 0.79-0.96) or birth weight (RR: 0.91, 95% CI, 0.82-1.00). The main cause of stillbirth was intrauterine asphyxia due to placental causes (67.6%) or cord pathology (12.6%), the most frequently encountered maternal pathology was cardiovascular (28.3%) or infectious (21.7%). Our study revealed no significant changes in terms of maternal and neonatal characteristics during the two-year pandemic period.

Conclusions: Lockdown restrictions in Bihor County, Romania were associated with an increase in stillbirths, whilst preterm birth rate decreased. This raises concerns about whether pandemic policy measures may have led to a failure in identifying and offering proper care for pregnant women who were more likely to experience an antepartum loss. Further studies across the globe are needed in order to integrate comparable data that will help develop adequate protocols and policies for protecting maternal and child health during the next pandemic that will follow.

背景:关于 COVID-19 大流行病政策措施对孕产妇和新生儿健康的影响,国际研究报告的数据相互矛盾。据报道,对死产和早产的影响很大。已发表的文献表明,经济环境影响了强加的缓解措施的效果,对低收入国家的影响更为严重:我们的目标是比较 COVID-19 大流行之前和期间罗马尼亚比霍尔县唯一一家三级妇产医院的妊娠结局。本研究旨在观察和记录这两个时期围产期结果的差异,但不推断与大流行或其相关限制因素的直接因果关系:我们利用比霍尔公共卫生服务登记处的数据,对罗马尼亚比霍尔县 COVID-19 大流行期间的早产和死胎进行了回顾性队列分析。将大流行期间(2020 年 3 月至 2022 年 2 月)的妊娠结局与 COVID-19 前的相应历史时期(2018 年 3 月至 2020 年 2 月)进行了比较。此外,还研究了这些时期的孕产妇社会人口变量和新生儿特征:结果:COVID-19 大流行期间的死胎率上升(RR:1.53,95% CI,1.05-2.23)。早产在这一时期受到明显影响,并且在分析胎龄(RR:0.88,95% CI,0.79-0.96)或出生体重(RR:0.91,95% CI,0.82-1.00)时也显示出变化。死胎的主要原因是胎盘原因(67.6%)或脐带病变(12.6%)导致的宫内窒息,最常见的产妇病变是心血管疾病(28.3%)或感染性疾病(21.7%)。我们的研究表明,在两年的大流行期间,产妇和新生儿的特征没有发生重大变化:罗马尼亚比霍尔县的封锁限制措施与死产增加有关,而早产率则有所下降。这引发了人们的担忧:大流行病的政策措施是否会导致无法识别并为更有可能经历产前损失的孕妇提供适当的护理。需要在全球范围内开展进一步研究,以便整合可比数据,帮助制定适当的规程和政策,在下一次大流行期间保护孕产妇和儿童健康。
{"title":"Preterm birth and stillbirth during COVID-19 pandemic in Bihor County/Romania.","authors":"Radu Galis, Paula Trif, Diana Mudura, Romina Murvai, Lucia Georgeta Daina, Florin Szasz, Rodica Negrini, Adrian Hatos, Beáta Fatime Gyarmati, Mandy C Daly, Jan Mazela, Boris W Kramer","doi":"10.3389/frph.2024.1286496","DOIUrl":"10.3389/frph.2024.1286496","url":null,"abstract":"<p><strong>Background: </strong>International studies have reported conflicting data about the effects of COVID-19 pandemic policy measures on maternal and neonatal health. A major impact was reported on stillbirth and prematurity. The published literature suggests that the economic setting influenced the effects of imposed mitigation measures with a more severe effect in low-income countries.</p><p><strong>Objectives: </strong>Our objective is to compare pregnancy outcomes at the only tertiary Maternity Hospital in Bihor County-Romania before and during the COVID-19 pandemic. This study aims to observe and document differences in perinatal outcomes across these periods, without inferring direct causation related to the pandemic or its associated restrictions.</p><p><strong>Materials and methods: </strong>We used data from the registries of Public Health Services Bihor to conduct a retrospective cohort analysis of preterm births and stillbirths during the COVID-19 pandemic in Bihor County, Romania. Pregnancy outcomes were compared between the pandemic period (March 2020-February 2022) to the corresponding historical pre-COVID-19 period (March 2018-February 2020). Maternal socio-demographic variables and neonatal characteristics of these periods were also examined.</p><p><strong>Results: </strong>The COVID-19 pandemic period was associated with an increase in the stillbirth rate (RR: 1.53, 95% CI, 1.05-2.23). Preterm birth was significantly impacted during this period and showed changes when analyzing gestational age (RR: 0.88, 95% CI, 0.79-0.96) or birth weight (RR: 0.91, 95% CI, 0.82-1.00). The main cause of stillbirth was intrauterine asphyxia due to placental causes (67.6%) or cord pathology (12.6%), the most frequently encountered maternal pathology was cardiovascular (28.3%) or infectious (21.7%). Our study revealed no significant changes in terms of maternal and neonatal characteristics during the two-year pandemic period.</p><p><strong>Conclusions: </strong>Lockdown restrictions in Bihor County, Romania were associated with an increase in stillbirths, whilst preterm birth rate decreased. This raises concerns about whether pandemic policy measures may have led to a failure in identifying and offering proper care for pregnant women who were more likely to experience an antepartum loss. Further studies across the globe are needed in order to integrate comparable data that will help develop adequate protocols and policies for protecting maternal and child health during the next pandemic that will follow.</p>","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"6 ","pages":"1286496"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Multipurpose prevention technologies for HIV, STIs and pregnancies. 社论:艾滋病、性传播感染和怀孕的多用途预防技术。
IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-02-27 eCollection Date: 2024-01-01 DOI: 10.3389/frph.2024.1384153
Barbara A Friedland, Andrea Ries Thurman, Harriet Nuwagaba-Biribonwoha, R Karl Malcolm
{"title":"Editorial: Multipurpose prevention technologies for HIV, STIs and pregnancies.","authors":"Barbara A Friedland, Andrea Ries Thurman, Harriet Nuwagaba-Biribonwoha, R Karl Malcolm","doi":"10.3389/frph.2024.1384153","DOIUrl":"10.3389/frph.2024.1384153","url":null,"abstract":"","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"6 ","pages":"1384153"},"PeriodicalIF":2.3,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10927752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140112343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the costs and perceived benefits of oral pre-exposure prophylaxis (PrEP) delivery in ten counties of Kenya: a costing and a contingent valuation study. 估算肯尼亚十个县提供口服暴露前预防疗法(PrEP)的成本和预期收益:成本计算和或有估值研究。
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-02-23 eCollection Date: 2024-01-01 DOI: 10.3389/frph.2024.1278764
Steven Forsythe, Urbanus Kioko, Guy Mahiane, Robert Glaubius, Abednego Musau, Anthony Gichangi, Jason Reed, Daniel Were
<p><strong>Background: </strong>Kenya included oral PrEP in the national guidelines as part of combination HIV prevention, and subsequently began providing PrEP to individuals who are at elevated risk of HIV infection in 2017. However, as scale-up continued, there was a recognized gap in knowledge on the cost of delivering oral PrEP. This gap limited the ability of the Government of Kenya to budget for its PrEP scale-up and to evaluate PrEP relative to other HIV prevention strategies. The following study calculated the actual costs of oral PrEP scale-up as it was being delivered in ten counties in Kenya. This costing also allowed for a comparison of various models of service delivery in different geographic regions from the perspective of service providers in Kenya. In addition, the analysis was also conducted to understand factors that indicate why some individuals place a greater value on PrEP than others, using a contingent valuation technique.</p><p><strong>Methods: </strong>Data collection was completed between November 2017 and September 2018. Costing data was collected from 44 Kenyan health facilities, consisting of 23 public facilities, 5 private facilities and 16 drop-in centers (DICEs) through a cross-sectional survey in ten counties. Financial and programmatic data were collected from financial and asset records and through interviewer administered questionnaires. The costs associated with PrEP provision were calculated using an ingredients-based costing approach which involved identification and costing of all the economic inputs (both direct and indirect) used in PrEP service delivery. In addition, a contingent valuation study was conducted at the same 44 facilities to understand factors that reveal why some individuals place a greater value on PrEP than others. Interviews were conducted with 2,258 individuals (1,940 current PrEP clients and 318 non-PrEP clients). A contingent valuation method using a "payment card approach" was used to determine the maximum willingness to pay (WTP) of respondents regarding obtaining access to oral PrEP services.</p><p><strong>Results: </strong>The weighted cost of providing PrEP was $253 per person year, ranging from $217 at health centers to $283 at dispensaries. Drop-in centers (DICEs), which served about two-thirds of the client volume at surveyed facilities, had a unit cost of $276. The unit cost was highest for facilities targeting MSM ($355), while it was lowest for those targeting FSW ($248). The unit cost for facilities targeting AGYW was $323 per person year. The largest percentage of costs were attributable to personnel (58.5%), followed by the cost of drugs, which represented 25% of all costs. The median WTP for PrEP was $2 per month (mean was $4.07 per month). This covers only one-third of the monthly cost of the medication (approximately $6 per month) and less than 10% of the full cost of delivering PrEP ($21 per month). A sizable proportion of current clients (27%) were unwilling to pa
背景:肯尼亚将口服 PrEP 作为艾滋病综合预防的一部分纳入国家指导方针,随后于 2017 年开始向艾滋病感染风险较高的个人提供 PrEP。然而,随着规模的不断扩大,在提供口服 PrEP 的成本方面存在公认的知识差距。这一差距限制了肯尼亚政府为扩大 PrEP 规模编制预算的能力,也限制了肯尼亚政府评估 PrEP 与其他艾滋病毒预防策略相比的能力。以下研究计算了在肯尼亚十个县推广口服 PrEP 的实际成本。通过成本计算,还可以从肯尼亚服务提供者的角度对不同地理区域的各种服务提供模式进行比较。此外,还利用或有估值技术进行了分析,以了解表明为何一些人比其他人更重视 PrEP 的因素:数据收集工作于 2017 年 11 月至 2018 年 9 月期间完成。通过在 10 个县进行横断面调查,从 44 家肯尼亚医疗机构(包括 23 家公共医疗机构、5 家私营医疗机构和 16 家救助中心 (DICE))收集了成本计算数据。财务和项目数据通过财务和资产记录以及访谈人员发放的调查问卷收集。与提供 PrEP 相关的成本采用基于成分的成本计算方法进行计算,该方法涉及对 PrEP 服务中使用的所有经济投入(包括直接投入和间接投入)进行识别和成本计算。此外,还在同样的 44 家机构开展了一项或有估值研究,以了解揭示某些人比其他人更重视 PrEP 的原因。对 2,258 人进行了访谈(1,940 名 PrEP 现有客户和 318 名非 PrEP 客户)。采用 "支付卡法 "的或然估价法确定受访者对获得口服 PrEP 服务的最大支付意愿(WTP):提供 PrEP 的加权成本为每人每年 253 美元,从保健中心的 217 美元到药房的 283 美元不等。在接受调查的医疗机构中,约有三分之二的服务对象选择了投宿中心(DICEs),其单位成本为 276 美元;针对男男性行为者(MSM)的医疗机构的单位成本最高(355 美元),而针对女性同性恋者(FSW)的医疗机构的单位成本最低(248 美元)。针对 AGYW 的机构的单位成本为每人每年 323 美元。人员成本所占比例最大(58.5%),其次是药物成本,占所有成本的 25%。PrEP 的 WTP 中位数为每月 2 美元(平均值为每月 4.07 美元)。这仅占每月药费(约 6 美元/月)的三分之一,不到 PrEP 全部费用(21 美元/月)的 10%。相当一部分现有客户(27%)不愿意为 PrEP 支付任何费用。某些人群更看重 PrEP 服务,包括讨论:这是关于肯尼亚 PrEP 服务成本的最新、最全面的研究。这些结果将用于确定资源需求和调动资源,以促进 PrEP 在肯尼亚及其他国家的可持续推广。这项或然估值研究对肯尼亚的 PrEP 计划具有重要意义。首先,它表明某些人群采用口服 PrEP 的积极性更高,这体现在他们对该服务的 WTP 更高。例如,男男性行为者(MSM)和女性外阴残割者(FSW)对 PrEP 的重视程度高于女性外阴残割者(AGYW)。反过来,教育程度较高的人对 PrEP 的重视程度也远远高于教育程度较低的人(这可能也反映了教育程度较高的人 "支付能力 "较强)。这表明,任何增加需求或改善 PrEP 持续性的尝试都应考虑到客户群体的这些差异。从现有的 PrEP 患者身上收回成本可能会对其接受率和持续率产生负面影响。
{"title":"Estimating the costs and perceived benefits of oral pre-exposure prophylaxis (PrEP) delivery in ten counties of Kenya: a costing and a contingent valuation study.","authors":"Steven Forsythe, Urbanus Kioko, Guy Mahiane, Robert Glaubius, Abednego Musau, Anthony Gichangi, Jason Reed, Daniel Were","doi":"10.3389/frph.2024.1278764","DOIUrl":"10.3389/frph.2024.1278764","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Kenya included oral PrEP in the national guidelines as part of combination HIV prevention, and subsequently began providing PrEP to individuals who are at elevated risk of HIV infection in 2017. However, as scale-up continued, there was a recognized gap in knowledge on the cost of delivering oral PrEP. This gap limited the ability of the Government of Kenya to budget for its PrEP scale-up and to evaluate PrEP relative to other HIV prevention strategies. The following study calculated the actual costs of oral PrEP scale-up as it was being delivered in ten counties in Kenya. This costing also allowed for a comparison of various models of service delivery in different geographic regions from the perspective of service providers in Kenya. In addition, the analysis was also conducted to understand factors that indicate why some individuals place a greater value on PrEP than others, using a contingent valuation technique.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data collection was completed between November 2017 and September 2018. Costing data was collected from 44 Kenyan health facilities, consisting of 23 public facilities, 5 private facilities and 16 drop-in centers (DICEs) through a cross-sectional survey in ten counties. Financial and programmatic data were collected from financial and asset records and through interviewer administered questionnaires. The costs associated with PrEP provision were calculated using an ingredients-based costing approach which involved identification and costing of all the economic inputs (both direct and indirect) used in PrEP service delivery. In addition, a contingent valuation study was conducted at the same 44 facilities to understand factors that reveal why some individuals place a greater value on PrEP than others. Interviews were conducted with 2,258 individuals (1,940 current PrEP clients and 318 non-PrEP clients). A contingent valuation method using a \"payment card approach\" was used to determine the maximum willingness to pay (WTP) of respondents regarding obtaining access to oral PrEP services.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The weighted cost of providing PrEP was $253 per person year, ranging from $217 at health centers to $283 at dispensaries. Drop-in centers (DICEs), which served about two-thirds of the client volume at surveyed facilities, had a unit cost of $276. The unit cost was highest for facilities targeting MSM ($355), while it was lowest for those targeting FSW ($248). The unit cost for facilities targeting AGYW was $323 per person year. The largest percentage of costs were attributable to personnel (58.5%), followed by the cost of drugs, which represented 25% of all costs. The median WTP for PrEP was $2 per month (mean was $4.07 per month). This covers only one-third of the monthly cost of the medication (approximately $6 per month) and less than 10% of the full cost of delivering PrEP ($21 per month). A sizable proportion of current clients (27%) were unwilling to pa","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"6 ","pages":"1278764"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10920246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial vaginosis testing gaps for transmasculine patients may exacerbate health disparities. 跨性别患者的细菌性阴道病检测缺口可能会加剧健康差距。
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-02-20 eCollection Date: 2024-01-01 DOI: 10.3389/frph.2024.1344111
Hale M Thompson, Laura K Rusie, John A Schneider, Supriya D Mehta

Introduction: Bacterial vaginosis (BV) is associated with non-optimal changes in the vaginal microbiome and increased susceptibility to STIs and HIV in cisgender women. Much less is known about the sexual health of transmasculine people and susceptibility to BV, STIs, and HIV. This study's objective was to assess BV testing and outcomes of transmasculine and cisgender women patient populations at a large, LGBTQ + federally qualified health center.

Methods: Retrospective electronic health record data were extracted for eligible patients having at least one primary care visit between January 1, 2021, and December 31, 2021. Transmasculine patients were limited to those with a testosterone prescription in 2021. We conducted log binomial regression analysis to determine the probability of receiving a BV test based on gender identity, adjusting for sociodemographic characteristics.

Results: During 2021, 4,903 cisgender women patients and 1,867 transmasculine patients had at least one primary care visit. Compared to cisgender women, transmasculine patients were disproportionately young, White, queer, privately insured, living outside Chicago, and had a lower rate of BV testing (1.9% v. 17.3%, p < 0.001). Controlling for sociodemographics, transmasculine patients were less likely to receive a BV test [Prevalence Ratio = 0.19 (95% CI 0.13-0.27)].

Discussion: The low rate of BV testing among transmasculine patients may contribute to disparities in reproductive health outcomes. Prospective community- and provider-engaged research is needed to better understand the multifactorial determinants for sexual healthcare and gender-affirming care for transmasculine patients. In particular, the impact of exogenous testosterone on the vaginal microbiome should also be determined.

导言:细菌性阴道病(BV)与阴道微生物群的非最佳变化以及顺性别女性对性传播感染和艾滋病毒的易感性增加有关。人们对跨性别者的性健康以及对 BV、性传播感染和 HIV 的易感性知之甚少。本研究的目的是评估一家大型 LGBTQ + 联邦合格医疗中心的跨性别女性患者和顺性别女性患者的 BV 检测和结果:我们提取了符合条件的患者的回顾性电子健康记录数据,这些患者在 2021 年 1 月 1 日至 2021 年 12 月 31 日期间至少接受过一次初级保健就诊。跨性别患者仅限于在 2021 年开具睾酮处方的患者。我们进行了对数二项式回归分析,以确定根据性别认同接受 BV 检测的概率,并对社会人口学特征进行了调整:2021 年期间,4903 名顺性女性患者和 1867 名跨性别患者至少接受了一次初级保健就诊。与顺性别女性相比,跨性别患者中年轻、白人、同性恋、有私人保险、居住在芝加哥以外的比例偏高,BV 检测率较低(1.9% 对 17.3%,p 讨论):跨性别患者的 BV 检测率较低可能会导致生殖健康结果的差异。需要开展由社区和医疗服务提供者参与的前瞻性研究,以更好地了解跨性别患者性保健和性别确认护理的多因素决定因素。特别是,还应确定外源性睾酮对阴道微生物组的影响。
{"title":"Bacterial vaginosis testing gaps for transmasculine patients may exacerbate health disparities.","authors":"Hale M Thompson, Laura K Rusie, John A Schneider, Supriya D Mehta","doi":"10.3389/frph.2024.1344111","DOIUrl":"10.3389/frph.2024.1344111","url":null,"abstract":"<p><strong>Introduction: </strong>Bacterial vaginosis (BV) is associated with non-optimal changes in the vaginal microbiome and increased susceptibility to STIs and HIV in cisgender women. Much less is known about the sexual health of transmasculine people and susceptibility to BV, STIs, and HIV. This study's objective was to assess BV testing and outcomes of transmasculine and cisgender women patient populations at a large, LGBTQ + federally qualified health center.</p><p><strong>Methods: </strong>Retrospective electronic health record data were extracted for eligible patients having at least one primary care visit between January 1, 2021, and December 31, 2021. Transmasculine patients were limited to those with a testosterone prescription in 2021. We conducted log binomial regression analysis to determine the probability of receiving a BV test based on gender identity, adjusting for sociodemographic characteristics.</p><p><strong>Results: </strong>During 2021, 4,903 cisgender women patients and 1,867 transmasculine patients had at least one primary care visit. Compared to cisgender women, transmasculine patients were disproportionately young, White, queer, privately insured, living outside Chicago, and had a lower rate of BV testing (1.9% v. 17.3%, <i>p</i> < 0.001). Controlling for sociodemographics, transmasculine patients were less likely to receive a BV test [Prevalence Ratio = 0.19 (95% CI 0.13-0.27)].</p><p><strong>Discussion: </strong>The low rate of BV testing among transmasculine patients may contribute to disparities in reproductive health outcomes. Prospective community- and provider-engaged research is needed to better understand the multifactorial determinants for sexual healthcare and gender-affirming care for transmasculine patients. In particular, the impact of exogenous testosterone on the vaginal microbiome should also be determined.</p>","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"6 ","pages":"1344111"},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Key programmatic and policy considerations for introducing multipurpose prevention (MPT) methods: reflections from healthcare providers and key stakeholders in South Africa. 引入多用途预防(MPT)方法的主要计划和政策考虑因素:南非医疗服务提供者和主要利益相关者的思考。
IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-02-20 eCollection Date: 2024-01-01 DOI: 10.3389/frph.2024.1249750
Alison Kutywayo, Paballo Mataboge, Nqaba Mthimkhulu, Catherine E Martin, Lorrein S Muhwava, Mbali Mazibuko, Nthabiseng Makalela, Khanyiswa Kwatsha, Vusile Butler, Saiqa Mullick

Introduction: Multipurpose prevention technologies (MPTs) simultaneously prevent HIV, other sexually transmitted infections, and/or unintended pregnancy. Key gatekeepers, [healthcare providers (HCPs) and key stakeholders] require proactive engagement before product implementation. This manuscript identifies HCP demand creation strategies, key stakeholder considerations for the adoption of MPTs in South Africa.

Methods: Formative research was conducted in three districts in three South African provinces (July to November 2022). Nurses initiating oral PrEP at facility and mobile study sites participated in 4-hour participatory workshops, exploring HIV prevention, including MPTs, demand creation strategies, and preferred MPTs training packages. Activities were observed, transcribed, and thematically analysed. Five online in-depth interviews (IDIs) with Key informants (KIs) (National/district programme implementers and technical leads) and one in person, exploring key programmatic and policy considerations for MPT adoption. IDIs were approximately 40 min long, audio recorded, transcribed, and thematically analysed.

Results: Twenty-one Professional Nurses completed workshops: 19 female. Six IDIs were conducted with 4 Facility Managers, 1 NDoH representative and 1 DoH Provincial Deputy Director. All participants were females, aged 30-60+ years with >10 years' in SRH/HIV policy/advocacy/research. Community conversations and information at the clinic were the best MPT demand creation methods among HCPs. KIs identified five considerations for future MPT implementation: HCP training; demand creation and messaging; existing PrEP policy amendments; preparing users for additional choice; and sustaining MPT provision.

Conclusion: Contraceptive implant and oral PrEP implementation lessons learned should be proactively considered when preparing for MPT introduction. HCP training and demand creation are of particular importance before MPT introduction.

导言:多用途预防技术 (MPT) 可同时预防 HIV、其他性传播感染和/或意外怀孕。在产品实施之前,关键守门人(医疗保健提供者(HCPs)和主要利益相关者)需要积极主动地参与进来。本手稿确定了在南非采用 MPTs 的 HCP 需求创造策略和主要利益相关者的考虑因素:在南非三个省的三个地区开展了形成性研究(2022 年 7 月至 11 月)。在医疗机构和流动研究地点开展口服 PrEP 的护士参加了 4 小时的参与式研讨会,探讨包括 MPTs 在内的 HIV 预防、需求创造策略以及首选 MPTs 培训包。对活动进行了观察、记录和主题分析。与关键信息提供者(KIs)(国家/地区计划实施者和技术负责人)进行了五次在线深入访谈(IDIs),并亲自参加了一次访谈,探讨了采用 MPT 的主要计划和政策考虑因素。IDI 长约 40 分钟,经过录音、转录和主题分析:21 名专业护士完成了研讨会:19 名女性。与 4 名设施经理、1 名国家卫生部代表和 1 名卫生部省级副主任进行了 6 次 IDI。所有参与者均为女性,年龄在 30-60 岁以上,从事性健康和生殖健康/艾滋病政策/宣传/研究工作 10 年以上。社区谈话和在诊所提供信息是卫生保健人员创造 MPT 需求的最佳方法。KIs 确定了未来实施 MPT 的五个考虑因素:HCP 培训;需求创造和信息传递;现行 PrEP 政策修订;为用户提供更多选择做好准备;以及持续提供 MPT:结论:在准备引入 MPT 时,应积极考虑避孕植入物和口服 PrEP 的实施经验。在引入 MPT 之前,HCP 培训和需求创造尤为重要。
{"title":"Key programmatic and policy considerations for introducing multipurpose prevention (MPT) methods: reflections from healthcare providers and key stakeholders in South Africa.","authors":"Alison Kutywayo, Paballo Mataboge, Nqaba Mthimkhulu, Catherine E Martin, Lorrein S Muhwava, Mbali Mazibuko, Nthabiseng Makalela, Khanyiswa Kwatsha, Vusile Butler, Saiqa Mullick","doi":"10.3389/frph.2024.1249750","DOIUrl":"10.3389/frph.2024.1249750","url":null,"abstract":"<p><strong>Introduction: </strong>Multipurpose prevention technologies (MPTs) simultaneously prevent HIV, other sexually transmitted infections, and/or unintended pregnancy. Key gatekeepers, [healthcare providers (HCPs) and key stakeholders] require proactive engagement before product implementation. This manuscript identifies HCP demand creation strategies, key stakeholder considerations for the adoption of MPTs in South Africa.</p><p><strong>Methods: </strong>Formative research was conducted in three districts in three South African provinces (July to November 2022). Nurses initiating oral PrEP at facility and mobile study sites participated in 4-hour participatory workshops, exploring HIV prevention, including MPTs, demand creation strategies, and preferred MPTs training packages. Activities were observed, transcribed, and thematically analysed. Five online in-depth interviews (IDIs) with Key informants (KIs) (National/district programme implementers and technical leads) and one in person, exploring key programmatic and policy considerations for MPT adoption. IDIs were approximately 40 min long, audio recorded, transcribed, and thematically analysed.</p><p><strong>Results: </strong>Twenty-one Professional Nurses completed workshops: 19 female. Six IDIs were conducted with 4 Facility Managers, 1 NDoH representative and 1 DoH Provincial Deputy Director. All participants were females, aged 30-60+ years with >10 years' in SRH/HIV policy/advocacy/research. Community conversations and information at the clinic were the best MPT demand creation methods among HCPs. KIs identified five considerations for future MPT implementation: HCP training; demand creation and messaging; existing PrEP policy amendments; preparing users for additional choice; and sustaining MPT provision.</p><p><strong>Conclusion: </strong>Contraceptive implant and oral PrEP implementation lessons learned should be proactively considered when preparing for MPT introduction. HCP training and demand creation are of particular importance before MPT introduction.</p>","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"6 ","pages":"1249750"},"PeriodicalIF":2.3,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10912167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140041020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy 基于单克隆抗体的多用途预防技术(MPT)在预防性传播感染和意外怀孕方面的创新成果
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-01-09 DOI: 10.3389/frph.2023.1337479
S. Dohadwala, Matthew T. Geib, J. Politch, Deborah J. Anderson
Monoclonal antibodies (mAbs) are currently being produced for a number of clinical applications including contraception and the prevention of sexually transmitted infections (STIs). Combinations of contraceptive and anti-STI mAbs, including antibodies against HIV-1 and HSV-2, provide a powerful and flexible approach for highly potent and specific multipurpose prevention technology (MPT) products with desirable efficacy, safety and pharmacokinetic profiles. MAbs can be administered systemically by injection, or mucosally via topical products (e.g., films, gels, rings) which can be tailored for vaginal, penile or rectal administration to address the needs of different populations. The MPT field has faced challenges with safety, efficacy, production and cost. Here, we review the state-of-the-art of mAb MPTs that tackle these challenges with innovative strategies in mAb engineering, manufacturing, and delivery that could usher in a new generation of safe, efficacious, cost-effective, and scalable mAb MPTs.
目前生产的单克隆抗体 (mAbs) 有多种临床应用,包括避孕和预防性传播感染 (STI)。避孕药和抗 STI mAbs(包括抗 HIV-1 和 HSV-2 的抗体)的组合,为具有理想疗效、安全性和药代动力学特征的高效特异性多用途预防技术(MPT)产品提供了一种强大而灵活的方法。MAbs 可通过注射进行全身给药,也可通过外用产品(如薄膜、凝胶、环)进行粘膜给药,这些产品可根据阴道、阴茎或直肠给药进行定制,以满足不同人群的需求。MPT 领域面临着安全性、有效性、生产和成本方面的挑战。在此,我们回顾了利用 mAb 工程、制造和给药方面的创新策略应对这些挑战的 mAb MPT 的最新进展,这些策略可能会带来新一代安全、有效、经济高效且可扩展的 mAb MPT。
{"title":"Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy","authors":"S. Dohadwala, Matthew T. Geib, J. Politch, Deborah J. Anderson","doi":"10.3389/frph.2023.1337479","DOIUrl":"https://doi.org/10.3389/frph.2023.1337479","url":null,"abstract":"Monoclonal antibodies (mAbs) are currently being produced for a number of clinical applications including contraception and the prevention of sexually transmitted infections (STIs). Combinations of contraceptive and anti-STI mAbs, including antibodies against HIV-1 and HSV-2, provide a powerful and flexible approach for highly potent and specific multipurpose prevention technology (MPT) products with desirable efficacy, safety and pharmacokinetic profiles. MAbs can be administered systemically by injection, or mucosally via topical products (e.g., films, gels, rings) which can be tailored for vaginal, penile or rectal administration to address the needs of different populations. The MPT field has faced challenges with safety, efficacy, production and cost. Here, we review the state-of-the-art of mAb MPTs that tackle these challenges with innovative strategies in mAb engineering, manufacturing, and delivery that could usher in a new generation of safe, efficacious, cost-effective, and scalable mAb MPTs.","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"58 27","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139441813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda 孕期每日口服 PrEP 对乌干达少女和年轻妇女骨矿物质密度的影响
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-01-08 DOI: 10.3389/frph.2023.1240990
Kidist Zewdie, F. Kiweewa, Timothy Ssebuliba, Susan A. Morrison, Timothy R Muwonge, Jade Boyer, Felix Bambia, Josephine Badaru, Gabrielle Stein, K. Mugwanya, Christina Wyatt, Michael T. Yin, A. Mujugira, Renee Heffron
Oral pre-exposure prophylaxis (PrEP) is recommended during pregnancy for at-risk cisgender women. Pregnancy is known to impede bone growth and tenofovir-based PrEP may also yield detrimental changes to bone health. Thus, we evaluated the effect of PrEP use during pregnancy on bone mineral density (BMD).We used data from a cohort of women who were sexually active, HIV-negative, ages 16–25 years, initiating DMPA or choosing condoms for contraception and enrolled in the Kampala Women's Bone Study. Women were followed quarterly with rapid testing for HIV and pregnancy, PrEP dispensation, and adherence counseling. Those who became pregnant were counseled on PrEP use during pregnancy per national guidelines. BMD of the neck of the hip, total hip, and lumbar spine was measured using dual-energy x-ray absorptiometry at baseline and annually. We compared the mean percent change in BMD from baseline to month 24.Among 499 women enrolled in the study, 105 pregnancies occurred in 90 women. At enrollment, the median age was 20 years (IQR: 19–21) and 89% initiated PrEP. During pregnancy, 67% of women continued using PrEP and PrEP was dispensed in 64% of visits. BMD declined significantly in women using PrEP during pregnancy compared to women who were not pregnant nor used PrEP: relative BMD change was −2.26% (95% CI: −4.63 to 0.11, p = 0.06) in the femoral neck, −2.57% (95% CI: −4.48 to −0.66, p = 0.01) in total hip, −3.06% (95% CI: −5.49 to −0.63, p = 0.001) lumbar spine. There was no significant difference in BMD loss when comparing PrEP-exposed pregnant women to pregnant women who never used PrEP. Women who became pregnant were less likely to continue PrEP at subsequent study visits than women who did not become pregnant (adjOR: 0.25, 95% CI: 0.16–0.37, p < 0.001). Based on pill counts, there was a 62% reduction in the odds of high PrEP adherence during pregnancy (adjOR = 0.38, 95% CI: 0.27–0.58, p < 0.001).Women who used PrEP during pregnancy experienced a similar reduction in BMD as pregnant women with no PrEP exposure, indicating that BMD loss in PrEP-using pregnant women is largely driven by pregnancy and not PrEP.
建议高危顺性女性在怀孕期间口服暴露前预防药物(PrEP)。众所周知,怀孕会阻碍骨骼生长,而基于替诺福韦的 PrEP 也可能对骨骼健康产生不利影响。因此,我们评估了孕期使用 PrEP 对骨矿物质密度(BMD)的影响。我们使用的数据来自性活跃、HIV 阴性、16-25 岁、开始使用 DMPA 或选择安全套避孕并参加坎帕拉女性骨研究的女性队列。每季度对妇女进行一次随访,对其进行 HIV 和妊娠快速检测,发放 PrEP,并为其提供坚持治疗方面的咨询。根据国家指导方针,怀孕妇女在怀孕期间接受了关于使用 PrEP 的咨询。在基线期和每年使用双能 X 射线吸收测量法测量髋关节颈、全髋和腰椎的 BMD。我们比较了从基线到第 24 个月期间 BMD 的平均百分比变化。在参加研究的 499 名妇女中,有 90 名妇女怀孕 105 次。入组时,中位年龄为 20 岁(IQR:19-21 岁),89% 的妇女开始接受 PrEP 治疗。怀孕期间,67% 的妇女继续使用 PrEP,64% 的就诊者获得了 PrEP。与未怀孕也未使用 PrEP 的妇女相比,怀孕期间使用 PrEP 的妇女的 BMD 明显下降:股骨颈的相对 BMD 变化为 -2.26%(95% CI:-4.63 至 0.11,p = 0.06),全髋的相对 BMD 变化为 -2.57%(95% CI:-4.48 至 -0.66,p = 0.01),腰椎的相对 BMD 变化为 -3.06%(95% CI:-5.49 至 -0.63,p = 0.001)。与接触过 PrEP 的孕妇相比,从未使用过 PrEP 的孕妇在 BMD 损失方面没有明显差异。与未怀孕的女性相比,怀孕女性在随后的研究访问中继续使用 PrEP 的可能性较低(adjOR:0.25,95% CI:0.16-0.37,p <0.001)。根据服药次数,怀孕期间高度坚持 PrEP 的几率降低了 62%(adjOR = 0.38,95% CI:0.27-0.58,p < 0.001)。怀孕期间使用 PrEP 的女性与未接触过 PrEP 的孕妇的 BMD 下降情况相似,这表明使用 PrEP 的孕妇的 BMD 下降主要是由怀孕而非 PrEP 引起的。
{"title":"The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda","authors":"Kidist Zewdie, F. Kiweewa, Timothy Ssebuliba, Susan A. Morrison, Timothy R Muwonge, Jade Boyer, Felix Bambia, Josephine Badaru, Gabrielle Stein, K. Mugwanya, Christina Wyatt, Michael T. Yin, A. Mujugira, Renee Heffron","doi":"10.3389/frph.2023.1240990","DOIUrl":"https://doi.org/10.3389/frph.2023.1240990","url":null,"abstract":"Oral pre-exposure prophylaxis (PrEP) is recommended during pregnancy for at-risk cisgender women. Pregnancy is known to impede bone growth and tenofovir-based PrEP may also yield detrimental changes to bone health. Thus, we evaluated the effect of PrEP use during pregnancy on bone mineral density (BMD).We used data from a cohort of women who were sexually active, HIV-negative, ages 16–25 years, initiating DMPA or choosing condoms for contraception and enrolled in the Kampala Women's Bone Study. Women were followed quarterly with rapid testing for HIV and pregnancy, PrEP dispensation, and adherence counseling. Those who became pregnant were counseled on PrEP use during pregnancy per national guidelines. BMD of the neck of the hip, total hip, and lumbar spine was measured using dual-energy x-ray absorptiometry at baseline and annually. We compared the mean percent change in BMD from baseline to month 24.Among 499 women enrolled in the study, 105 pregnancies occurred in 90 women. At enrollment, the median age was 20 years (IQR: 19–21) and 89% initiated PrEP. During pregnancy, 67% of women continued using PrEP and PrEP was dispensed in 64% of visits. BMD declined significantly in women using PrEP during pregnancy compared to women who were not pregnant nor used PrEP: relative BMD change was −2.26% (95% CI: −4.63 to 0.11, p = 0.06) in the femoral neck, −2.57% (95% CI: −4.48 to −0.66, p = 0.01) in total hip, −3.06% (95% CI: −5.49 to −0.63, p = 0.001) lumbar spine. There was no significant difference in BMD loss when comparing PrEP-exposed pregnant women to pregnant women who never used PrEP. Women who became pregnant were less likely to continue PrEP at subsequent study visits than women who did not become pregnant (adjOR: 0.25, 95% CI: 0.16–0.37, p < 0.001). Based on pill counts, there was a 62% reduction in the odds of high PrEP adherence during pregnancy (adjOR = 0.38, 95% CI: 0.27–0.58, p < 0.001).Women who used PrEP during pregnancy experienced a similar reduction in BMD as pregnant women with no PrEP exposure, indicating that BMD loss in PrEP-using pregnant women is largely driven by pregnancy and not PrEP.","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"27 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial and ethnic disparities in preterm birth: a mediation analysis incorporating mixtures of polybrominated diphenyl ethers 早产中的种族和民族差异:包含多溴联苯醚混合物的中介分析
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-01-08 DOI: 10.3389/frph.2023.1285444
Zifan Wang, Cuilin Zhang, Paige L. Williams, A. Bellavia, Blair J. Wylie, Kurunthachalam Kannan, Michael S. Bloom, Kelly J. Hunt, T. James-Todd
Racial and ethnic disparities persist in preterm birth (PTB) and gestational age (GA) at delivery in the United States. It remains unclear whether exposure to environmental chemicals contributes to these disparities.We applied recent methodologies incorporating environmental mixtures as mediators in causal mediation analysis to examine whether racial and ethnic disparities in GA at delivery and PTB may be partially explained by exposures to polybrominated diphenyl ethers (PBDEs), a class of chemicals used as flame retardants in the United States.Data from a multiracial/ethnic US cohort of 2008 individuals with low-risk singleton pregnancies were utilized, with plasma PBDE concentrations measured during early pregnancy. We performed mediation analyses incorporating three forms of mediators: (1) reducing all PBDEs to a weighted index, (2) selecting a PBDE congener, or (3) including all congeners simultaneously as multiple mediators, to evaluate whether PBDEs may contribute to the racial and ethnic disparities in PTB and GA at delivery, adjusted for potential confounders.Among the 2008 participants, 552 self-identified as non-Hispanic White, 504 self-identified as non-Hispanic Black, 568 self-identified as Hispanic, and 384 self-identified as Asian/Pacific Islander. The non-Hispanic Black individuals had the highest mean ∑PBDEs, the shortest mean GA at delivery, and the highest rate of PTB. Overall, the difference in GA at delivery comparing non-Hispanic Black to non-Hispanic White women was −0.30 (95% CI: −0.54, −0.05) weeks. This disparity reduced to −0.23 (95% CI: −0.49, 0.02) and −0.18 (95% CI: −0.46, 0.10) weeks if fixing everyone's weighted index of PBDEs to the median and the 25th percentile levels, respectively. The proportion of disparity mediated by the weighted index of PBDEs was 11.8%. No statistically significant mediation was found for PTB, other forms of mediator(s), or other racial and ethnic groups.PBDE mixtures may partially mediate the Black vs. White disparity in GA at delivery. While further validations are needed, lowering the PBDEs at the population level might help reduce this disparity.
在美国,早产(PTB)和分娩时胎龄(GA)方面持续存在种族和民族差异。我们采用最新的方法,将环境混合物作为因果中介分析中的中介物,来研究分娩时胎龄(GA)和早产(PTB)的种族和民族差异是否可部分归因于多溴联苯醚(PBDEs)的暴露,多溴联苯醚是美国用作阻燃剂的一类化学品。我们利用了美国一个多种族队列的数据,该队列由 2008 名低风险单胎妊娠者组成,在妊娠早期测量了血浆中的多溴联苯醚浓度。我们结合三种形式的中介因素进行了中介分析:(在 2008 年的参与者中,有 552 人自我认定为非西班牙裔白人,504 人自我认定为非西班牙裔黑人,568 人自我认定为西班牙裔,384 人自我认定为亚洲/太平洋岛民。非西班牙裔黑人的∑PBDEs 平均值最高,平均分娩 GA 值最短,PTB 发生率最高。总体而言,非西班牙裔黑人妇女与非西班牙裔白人妇女的产时总孕期差异为-0.30(95% CI:-0.54,-0.05)周。如果将每个人的多溴联苯醚加权指数分别固定在中位数和第 25 百分位数水平上,则这一差距分别降至-0.23(95% CI:-0.49,0.02)周和-0.18(95% CI:-0.46,0.10)周。由多溴联苯醚加权指数调节的差异比例为 11.8%。多溴联苯醚混合物可能部分调节了黑人与白人在分娩时性别差异方面的差异。多溴联苯醚混合物可能部分调节了黑人与白人在分娩时的性别差异,尽管还需要进一步验证,但在人群中降低多溴联苯醚含量可能有助于减少这种差异。
{"title":"Racial and ethnic disparities in preterm birth: a mediation analysis incorporating mixtures of polybrominated diphenyl ethers","authors":"Zifan Wang, Cuilin Zhang, Paige L. Williams, A. Bellavia, Blair J. Wylie, Kurunthachalam Kannan, Michael S. Bloom, Kelly J. Hunt, T. James-Todd","doi":"10.3389/frph.2023.1285444","DOIUrl":"https://doi.org/10.3389/frph.2023.1285444","url":null,"abstract":"Racial and ethnic disparities persist in preterm birth (PTB) and gestational age (GA) at delivery in the United States. It remains unclear whether exposure to environmental chemicals contributes to these disparities.We applied recent methodologies incorporating environmental mixtures as mediators in causal mediation analysis to examine whether racial and ethnic disparities in GA at delivery and PTB may be partially explained by exposures to polybrominated diphenyl ethers (PBDEs), a class of chemicals used as flame retardants in the United States.Data from a multiracial/ethnic US cohort of 2008 individuals with low-risk singleton pregnancies were utilized, with plasma PBDE concentrations measured during early pregnancy. We performed mediation analyses incorporating three forms of mediators: (1) reducing all PBDEs to a weighted index, (2) selecting a PBDE congener, or (3) including all congeners simultaneously as multiple mediators, to evaluate whether PBDEs may contribute to the racial and ethnic disparities in PTB and GA at delivery, adjusted for potential confounders.Among the 2008 participants, 552 self-identified as non-Hispanic White, 504 self-identified as non-Hispanic Black, 568 self-identified as Hispanic, and 384 self-identified as Asian/Pacific Islander. The non-Hispanic Black individuals had the highest mean ∑PBDEs, the shortest mean GA at delivery, and the highest rate of PTB. Overall, the difference in GA at delivery comparing non-Hispanic Black to non-Hispanic White women was −0.30 (95% CI: −0.54, −0.05) weeks. This disparity reduced to −0.23 (95% CI: −0.49, 0.02) and −0.18 (95% CI: −0.46, 0.10) weeks if fixing everyone's weighted index of PBDEs to the median and the 25th percentile levels, respectively. The proportion of disparity mediated by the weighted index of PBDEs was 11.8%. No statistically significant mediation was found for PTB, other forms of mediator(s), or other racial and ethnic groups.PBDE mixtures may partially mediate the Black vs. White disparity in GA at delivery. While further validations are needed, lowering the PBDEs at the population level might help reduce this disparity.","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"28 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139445128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in characteristics and use of complementary and alternative methods for coping with endometriosis-associated acyclic pelvic pain across adolescence and adulthood 青春期和成年期应对与子宫内膜异位症相关的非周期性骨盆疼痛的补充和替代方法的特点和使用情况的差异
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-01-08 DOI: 10.3389/frph.2023.1306380
Jennifer M. Mongiovi, B. Wallace, McKenzie Goodwin, A. Vitonis, Sarah Karevicius, A. Shafrir, Naoko Sasamoto, A. DiVasta, C. Sieberg, Kathryn L. Terry, S. A. Missmer
Over four million women in the US alone have been diagnosed with endometriosis. For those living with this disease, surgery and hormonal treatment reduce associated pelvic pain in some, while others continue to experience life impacting pain. Therefore, identification of accessible and cost-effective methods of pain reduction to compliment current treatment is urgently needed. Our objective was to quantify the prevalence of complementary and alternative methods used to manage acyclic pelvic pain and their reported benefit among women of different age groups living with endometriosis.We used baseline questionnaire data from laparoscopically-confirmed endometriosis cases who completed a WERF EPHect compliant questionnaire in the longitudinal cohort of The Women's Health Study: From Adolescence to Adulthood (A2A). Participants with acyclic pelvic pain were asked to indicate specific methods or activities that either helped or worsened their pelvic/lower abdominal pain. Differences among age groups [adolescent (<18 years), young adult (18–25 years), and adult (>25 years)] were assessed using Fisher's exact test.Of the 357 participants included in analysis, sleep for coping was reported more frequently among adolescents (n = 59, 57.3%) compared to young adults (n = 40, 44.0%) and adults (n = 19, 31.1%; p = 0.004). Adolescents also reported more frequent use of music (n = 29, 21.2%) than young adults (n = 10, 7.0%) and adults (n = 7, 9.1%; p = 0.001). Exercise worsened pain most commonly among adolescents (n = 82, 59.9%), followed by younger adults (n = 67, 46.9%), and adults (n = 27, 35.1%; p = 0.002).Our analysis of participants in the A2A cohort showed that the prevalence of complementary and alternative methods used for coping with endometriosis-associated acyclic pelvic pain varied by age group. Future studies should aim to provide information that will further inform decisions in making care plans for managing endometriosis-associated pain that is effective, accessible, and tailored to the preferences of the patient.
仅在美国,就有四百多万妇女被诊断出患有子宫内膜异位症。对于那些患有这种疾病的人来说,手术和激素治疗可以减轻一些人的盆腔疼痛,而另一些人则继续忍受着影响生活的疼痛。因此,亟需找到方便且具有成本效益的减轻疼痛的方法来补充目前的治疗。我们使用了经腹腔镜确诊的子宫内膜异位症病例的基线问卷数据,这些病例在妇女健康研究的纵向队列中填写了符合 WERF EPHect 标准的问卷:从青春期到成年期 (A2A)。有非周期性骨盆疼痛的参与者被要求指出帮助或加重其骨盆/下腹疼痛的具体方法或活动。在纳入分析的 357 名参与者中,青少年(59 人,占 57.3%)与年轻成年人(40 人,占 44.0%)和成年人(19 人,占 31.1%;P = 0.004)相比,更常以睡眠来应对疼痛。青少年报告使用音乐的频率(n = 29,21.2%)也高于年轻成年人(n = 10,7.0%)和成年人(n = 7,9.1%;p = 0.001)。我们对 A2A 队列参与者的分析表明,不同年龄段的人在应对与子宫内膜异位症相关的非周期性盆腔疼痛时使用补充和替代方法的普遍程度不同。未来的研究应旨在提供相关信息,为制定有效、方便且符合患者偏好的子宫内膜异位症相关疼痛护理计划提供决策依据。
{"title":"Differences in characteristics and use of complementary and alternative methods for coping with endometriosis-associated acyclic pelvic pain across adolescence and adulthood","authors":"Jennifer M. Mongiovi, B. Wallace, McKenzie Goodwin, A. Vitonis, Sarah Karevicius, A. Shafrir, Naoko Sasamoto, A. DiVasta, C. Sieberg, Kathryn L. Terry, S. A. Missmer","doi":"10.3389/frph.2023.1306380","DOIUrl":"https://doi.org/10.3389/frph.2023.1306380","url":null,"abstract":"Over four million women in the US alone have been diagnosed with endometriosis. For those living with this disease, surgery and hormonal treatment reduce associated pelvic pain in some, while others continue to experience life impacting pain. Therefore, identification of accessible and cost-effective methods of pain reduction to compliment current treatment is urgently needed. Our objective was to quantify the prevalence of complementary and alternative methods used to manage acyclic pelvic pain and their reported benefit among women of different age groups living with endometriosis.We used baseline questionnaire data from laparoscopically-confirmed endometriosis cases who completed a WERF EPHect compliant questionnaire in the longitudinal cohort of The Women's Health Study: From Adolescence to Adulthood (A2A). Participants with acyclic pelvic pain were asked to indicate specific methods or activities that either helped or worsened their pelvic/lower abdominal pain. Differences among age groups [adolescent (<18 years), young adult (18–25 years), and adult (>25 years)] were assessed using Fisher's exact test.Of the 357 participants included in analysis, sleep for coping was reported more frequently among adolescents (n = 59, 57.3%) compared to young adults (n = 40, 44.0%) and adults (n = 19, 31.1%; p = 0.004). Adolescents also reported more frequent use of music (n = 29, 21.2%) than young adults (n = 10, 7.0%) and adults (n = 7, 9.1%; p = 0.001). Exercise worsened pain most commonly among adolescents (n = 82, 59.9%), followed by younger adults (n = 67, 46.9%), and adults (n = 27, 35.1%; p = 0.002).Our analysis of participants in the A2A cohort showed that the prevalence of complementary and alternative methods used for coping with endometriosis-associated acyclic pelvic pain varied by age group. Future studies should aim to provide information that will further inform decisions in making care plans for managing endometriosis-associated pain that is effective, accessible, and tailored to the preferences of the patient.","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"8 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139445922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is there any truth in the myth that IVF treatments involve weight gain? 试管婴儿治疗会导致体重增加的说法是否属实?
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-01-08 DOI: 10.3389/frph.2023.1327110
B. Saar-Ryss, Michael Shilo, Michael Friger, L. Grin, Yulia Michailov, S. Meltcer, Svetlana Zaks, J. Rabinson, T. Lazer, Shevach Friedler
To examine body weight change in women undergoing in vitro fertilization and embryo transfer (IVF-ET) using antagonist protocol after up to three treatment cycles.A prospective cohort study among IVF patients treated between 2018 and 2019. Each patient underwent weight measurement three times during the treatment cycle: before treatment, at the beginning of the hormonal stimulation, and at the completion of the cycle, on the day of the pregnancy test. Data were also analyzed according to the body mass index (BMI) groups for normal weight, overweight, and obese patients. Finally, weight changes were recorded following altogether 519 treatment cycles, 240, 131, and 148 cycles, for normal weight, overweight, and obese patients, respectively.The change in the patient's weight was clinically non-significant either during the waiting period or during gonadotropin administration, and overall, during the first, second, or third treatment cycles. The recorded mean total weight change of 0.26 ± 1.85, 0.4 ± 1.81, and 0.17 ± 1.7, after the first, second, or third treatment cycles, represent a change of 0.36%, 0.56%, and 0.23% of their initial weights, respectively. This change of less than 1% of the body weight falls short of the clinically significant weight gain of 5%–7%. Analyzing the data for the various BMI groups, the changes observed in body weight were under 1%, hence with no clinical significance.The findings of the study reject the myth that hormone therapy involves clinically significant weight gain, and this can lower the concerns of many patients who are candidates for treatment of assisted reproductive technology.
目的:研究使用拮抗剂方案进行体外受精和胚胎移植(IVF-ET)的女性在最多三个治疗周期后的体重变化。这是一项前瞻性队列研究,研究对象为2018年至2019年期间接受治疗的体外受精患者。每位患者在治疗周期内接受了三次体重测量:治疗前、激素刺激开始时和周期结束时,即妊娠试验当天。此外,还根据体重指数(BMI)对正常体重、超重和肥胖患者进行了数据分析。最后,记录了正常体重、超重和肥胖患者共 519 个治疗周期(分别为 240、131 和 148 个周期)后的体重变化。在第一、第二或第三个治疗周期后,记录的平均总重量变化分别为 0.26 ± 1.85、0.4 ± 1.81 和 0.17 ± 1.7,分别占初始体重的 0.36%、0.56% 和 0.23%。这一不足 1%的体重变化未达到临床上显著的体重增加 5%-7%的标准。分析不同体重指数组的数据,观察到的体重变化均在 1%以下,因此没有临床意义。这项研究的结果否定了激素治疗会导致体重明显增加的说法,这可以降低许多辅助生殖技术候选患者的顾虑。
{"title":"Is there any truth in the myth that IVF treatments involve weight gain?","authors":"B. Saar-Ryss, Michael Shilo, Michael Friger, L. Grin, Yulia Michailov, S. Meltcer, Svetlana Zaks, J. Rabinson, T. Lazer, Shevach Friedler","doi":"10.3389/frph.2023.1327110","DOIUrl":"https://doi.org/10.3389/frph.2023.1327110","url":null,"abstract":"To examine body weight change in women undergoing in vitro fertilization and embryo transfer (IVF-ET) using antagonist protocol after up to three treatment cycles.A prospective cohort study among IVF patients treated between 2018 and 2019. Each patient underwent weight measurement three times during the treatment cycle: before treatment, at the beginning of the hormonal stimulation, and at the completion of the cycle, on the day of the pregnancy test. Data were also analyzed according to the body mass index (BMI) groups for normal weight, overweight, and obese patients. Finally, weight changes were recorded following altogether 519 treatment cycles, 240, 131, and 148 cycles, for normal weight, overweight, and obese patients, respectively.The change in the patient's weight was clinically non-significant either during the waiting period or during gonadotropin administration, and overall, during the first, second, or third treatment cycles. The recorded mean total weight change of 0.26 ± 1.85, 0.4 ± 1.81, and 0.17 ± 1.7, after the first, second, or third treatment cycles, represent a change of 0.36%, 0.56%, and 0.23% of their initial weights, respectively. This change of less than 1% of the body weight falls short of the clinically significant weight gain of 5%–7%. Analyzing the data for the various BMI groups, the changes observed in body weight were under 1%, hence with no clinical significance.The findings of the study reject the myth that hormone therapy involves clinically significant weight gain, and this can lower the concerns of many patients who are candidates for treatment of assisted reproductive technology.","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"59 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in reproductive health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1